APP and Alzheimer disease: Long-term 30% CR prevents the accumulation of Aβ in Tg2576 mice [65], an AD mouse model with mutations in amyloid precursor protein (APP) that results in amyloid plaque development, as well as high levels of amyloidogenic Aβ40 and Aβ42 peptide by 8–10 months of age [66,67].